

Bod Australia Limited (ASX:BDA) is a developer, distributor and marketer of health products and supplements, with a focus on plant-based extracts including medicinal cannabis.

**CAPITAL STRUCTURE**

ASX code **BDA**  
 Shares on issue 88.7m  
 Market Capitalisation ~\$40.3m

**BOARD & MANAGEMENT**

Mr George Livery  
 Executive Chairman

Ms Jo Patterson  
 Chief Executive Officer

Mr Stephen Thompson  
 Executive Director

Mr Akash Bedi  
 Non-Executive Director

Mr Patrice Malard  
 Non-Executive Director

Mr Simon O’Loughlin  
 Non-Executive Director

Mr Simon Taylor  
 Non-Executive Director

Mr Stephen Kelly  
 Company Secretary

**CONTACT**


Level 1, 377 New South Head Rd  
 Double Bay, NSW 2028

**Medicinal cannabis prescription sales jump 95% month on month**

- **Bod dispensed 329 prescriptions for MediCabilis™ in August representing a 95% increase on July (169)**
- **Prescription uptake has increased rapidly over calendar year - 613 prescriptions dispensed in CY2019**
- **Large number of repeat customers - outlines physician and patient product satisfaction**
- **MediCabilis™ being used to treat a range of conditions including PTSD, chronic pain and neurological disorders**
- **Domestic growth expected to continue with uptake in the UK to begin shortly - additional market entries pending**

**Sydney, Australia – 3 September 2019:** Medicinal cannabis healthcare products company, Bod Australia Limited (“Bod”, the “Company”) (ASX: BDA), is pleased to advise that it is witnessing a continued increase in prescription volumes for its 5% CBD MediCabilis™ product domestically.

Bod advises that it dispensed 329 MediCabilis™ prescriptions in August 2019, representing an increase of 95% from July 2019 (July 2019 prescriptions totalled 169). Further, prescriptions for August represent a 467% increase on June 2019 (June 2019 prescriptions totalled 58).



**Image one:** month on month increase in prescription volumes

Bod is continuing to witness strong uptake through its distribution partnerships with Burleigh Heads Cannabis and its partner Company, Cannabis Doctors Australia (ASX announcement: 21 June 2019), as well as uptake from a 12 month trial being undertaken by research partner, Cannabis Access Clinics, relating to the treatment of Post Traumatic Stress Disorder (ASX announcement: 4 June 2019).

Pleasingly, Bod has observed consistent repeat prescriptions from patients and physicians, providing an indication of satisfaction from both consumers and medical professionals.

The Company is confident of increased growth over the coming months as MediCabilis™ is prescribed for additional medical conditions. Bod is also progressing initiatives to expand its international footprint and will update shareholders on these in the near term.

**CEO Jo Patterson said:** “We are pleased to have witnessed another substantial increase in medicinal cannabis prescriptions. Growth has been underpinned by uptake through distribution partners Burleigh Heads Cannabis and Cannabis Access Clinics, as well as through our physician education programs.

“It is pleasing to observe the amount of repeat prescriptions that the Company is receiving, as it clearly indicates the benefit it is providing to patients and product superiority.

“Bod is confident that it will continue growth in prescription volumes as it progresses relationships with distributors in new markets and commences dispensing in the United Kingdom in the coming weeks.”

- ENDS -

## ABOUT BOD AUSTRALIA

**Bod Australia Limited (ASX:BDA)** is a developer, distributor and marketer of health and skincare products. Bod works with plant based extracts, with specific expertise in leveraging the health benefits associated with cannabis and hemp.

Bod is actively developing a range of over-the-counter and prescription products based on its unique, standardised, pharmaceutical grade cannabis extracts.

The Company has a large distribution footprint in Australia, selling prescription and OTC products to over 1,000 retail outlets, including pharmacies, retail stores and healthcare chains. The Company also has distribution agreements with two of Australia’s largest pharmacy wholesalers providing it with access to over two thirds of the market. Bod is also actively building capability in key European markets that it witnesses near term growth prospects.

[BODAUSTRALIA.COM](http://BODAUSTRALIA.COM)

### For more information please contact:

Jo Patterson  
Chief Executive Officer  
[info@bodaustralia.com](mailto:info@bodaustralia.com)  
+61 2 9199 5018

Henry Jordan  
Six Degrees Investor Relations  
[henry.jordan@sdir.com.au](mailto:henry.jordan@sdir.com.au)  
+61 431 271 538